Clearview Diagnostics

ClearView Diagnostics was founded with the mission to revolutionize breast cancer detection through advanced AI technology. The company's core vision is to provide radiologists with a quick, accurate, and cost-effective tool for identifying breast cancer, thereby improving patient outcomes. ClearView Diagnostics offers a deep-learning/AI software system designed to detect breast cancer, which has received FDA 510(k) clearance. Their market focus includes both domestic and international healthcare providers, with extensive studies conducted in Mexico.

Notable affiliated individuals include key researchers and radiologists who have contributed to the development of the technology. The company has secured significant funding, including two rounds of grants from the National Institutes of Health (NIH). Among its key achievements is the FDA approval of its ClearView cCAD product in January 2017. The impact of ClearView Diagnostics lies in its potential to enhance early detection of breast cancer, thereby saving lives and reducing healthcare costs.